The FDA - approved antihelminthic drug,
pyrvinium pamoate (PPAM), was found in a screening for compounds that promoted β - catenin turnover and, thereby, inhibiting Wnt signaling in ovarian and other cancer cells (Table 1)[51, 56].
Pyrvinium pamoate changes alternative splicing of the serotonin receptor 2C by influencing its RNA structure.
The substituted quinoline
pyrvinium pamoate (PPAM) is a cyanine dye which has been used to treat pinworm (Enterobius vermicularis) infections as well as strongyloidiasis in humans [5, 27].
Pyrvinium pamoate inhibits proliferation of myeloma / erythro - leukemia cells by suppressing mitochondrial respiratory complex I and STAT3.
Anticancer activities of anthelminthics were reported for mebendazole by Mukhopadhyay et al. in 2002, for
pyrvinium pamoate (PPAM) by Esumi et al. in 2004 and for niclosamide by Wang et al. in 2009, respectively [8 - 10].
Ishii I, Harada Y, Kasahara T. Reprofiling a classical anthelmintic,
pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration.
The treatment of pinworm infections in humans (enterobiasis) with pyrvinium chloride and
pyrvinium pamoate.
An anticancer agent,
pyrvinium pamoate inhibits the NADH - fumarate reductase system - a unique mitochondrial energy metabolism in tumour microenvironments.
Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt / PKB down - regulation and GSK3 activation.
A prominent example is the proposal to implement anthelminthics, such as mebendazole, niclosamide and
pyrvinium pamoate, as novel anticancer drugs.
An anthelmintic drug,
pyrvinium pamoate, thwarts fibrosis and ameliorates myocardial contractile dysfunction in a mouse model of myocardial infarction.
Not exact matches
In particular,
pamoate is added to
pyrvinium to provide a slow release depot form of the drug [16,17].